Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overview
- 1 November 1997
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (13) , 2167-2170
- https://doi.org/10.1016/s0959-8049(97)00363-8
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trialsEuropean Journal Of Cancer, 1995
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian CancerJNCI Journal of the National Cancer Institute, 1995
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of Clinical Oncology, 1994
- Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.Journal of Clinical Oncology, 1994
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell linesBritish Journal of Cancer, 1993
- Taxol: A New Drug with Significant Activity as a Salvage Therapy in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 1993
- Coping with toxicities of docetaxel (TaxotereTM)Annals of Oncology, 1993
- Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.Journal of Clinical Oncology, 1992